Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.71 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488698 | 0.91 | MET (0.76) | METJAK2ALK | |
| SCHEMBL30452774 | 0.91 | MET (0.76) | METJAK2ALK | |
| SCHEMBL17310261 | 0.88 | MET (0.77) | METJAK2ALK | |
| SCHEMBL17310259 | 0.88 | MET (0.77) | METJAK2ALK | |
| SCHEMBL5930627 | 0.88 | MET (0.80) | METJAK2ALK | |
| SCHEMBL488502 | 0.88 | MET (0.80) | METJAK2ALK | |
| SCHEMBL30454268 | 0.88 | MET (0.84) | METJAK2ALK | |
| SCHEMBL487628 | 0.88 | MET (0.80) | METJAK2ALK | |
| SCHEMBL488807 | 0.88 | MET (0.80) | METJAK2ALK | |
| SCHEMBL30454343 | 0.88 | MET (0.80) | METJAK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786777-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | MET 1/4885JAK2 342/4885ALK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.